Compare CLPS & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | CVM |
|---|---|---|
| Founded | 2005 | 1983 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 24.1M |
| IPO Year | 2017 | 1996 |
| Metric | CLPS | CVM |
|---|---|---|
| Price | $0.81 | $1.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 8.9K | ★ 98.0K |
| Earning Date | 10-16-2026 | 11-24-2026 |
| Dividend Yield | ★ 14.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.80 | $0.89 |
| 52 Week High | $1.24 | $7.80 |
| Indicator | CLPS | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 36.57 |
| Support Level | $0.86 | $1.19 |
| Resistance Level | $0.95 | $1.52 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 31.58 | 10.17 |
CLPS Inc is information technology, consulting and solutions service provider, focused on delivering services mainly to world-wide institutions, including banking, wealth management, ecommerce, and automotive areas both in China and globally. It has been at the forefront of driving digital transformation and optimizing operational efficiency across industries through innovations in artificial intelligence (AI), cloud computing, and data. It diverse business lines span sectors including fintech, payment and credit services, e-commerce, education and study abroad programs, and world-wide tourism integrated with transportation services. Its segments are IT services and academic education service. Majority of revenue comes from IT services segment. Its products are NiBot RPA, and CAKU.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.